Evidence map›Paper›PMID 32736547›Full record

ArticleBMC endocrine disorders2020

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice.

Eliza B Geer, Jill Sisco, Daphne T Adelman, William H Ludlam, Asi Haviv, Shuqian Liu, Susan D Mathias, Dana Gelbaum, Lizheng Shi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Current treatment landscape of acromegaly.The Journal of clinical endocrinology and metabolism · 2026
    Review
  17. The acromegaly patient experience: burden of treatment and quality of life.The Journal of clinical endocrinology and metabolism · 2026
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Eliza B GeerMemorial Sloan Kettering, New York, NY, USA.
Jill SiscoAcromegaly Community, Grove, OK, USA.
Daphne T AdelmanNorthwestern University, Chicago, IL, USA.
William H LudlamChiasma, Inc, Waltham, MA, USA.
Asi HavivChiasma, Inc, Waltham, MA, USA.
Shuqian LiuTulane University, New Orleans, LA, USA.
Susan D MathiasHealth Outcomes Solutions, P.O. Box 2343, Winter Park, FL, 32790, USA. smathias@healthoutcomessolutions.com.ORCID http://orcid.org/0000-0002-2812-7033
Dana GelbaumChiasma, Inc, Waltham, MA, USA.
Lizheng ShiTulane University, New Orleans, LA, USA.
Chiasma (United States) · USTulane University · USHealth Outcomes Solutions (United States) · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAcromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, and joint pain, even those with normal IGF-1. Additionally, treatment with SRLs may cause injection site reactions and other side effects such as gastro-intestinal (GI) symptoms. This study utilized patient-reported outcome measures to examine the burden associated with acromegaly and its treatment for patients receiving a stable dose of long-acting SRLs in routine clinical practice.

methodsUS acromegaly patients on a stable dose of SRL seen by their treating healthcare provider in the past 12 months completed a one-time online survey including the Acro-TSQ, an acromegaly-specific tool for assessing symptom burden and treatment satisfaction and convenience.

resultsOne hundred five patients were enrolled (mean age 49.9 years, 79.1% female). Patients experienced numerous symptoms, including > 80% who experienced joint pain, acro-fog, swelling of soft tissue, and fatigue/weakness. Many symptoms occurred constantly, while some occurred at the end of the injection cycle, even among those with IGF-1 < = 1.0 ULN. Injection site reactions were common. Patients were moderately satisfied with their current treatment; symptoms and side effects often affected daily activities. On average, patients reported > 3 acromegaly provider visits/year.

conclusionsDespite receiving a stable dose of SRL and regular visits with an acromegaly healthcare provider, US acromegaly patients in routine clinical practice, and even the subgroup with normal IGF-1, report significant burden of disease and treatment.

Indexed as

AcromegalyAdultAgedAged, 80 and overCross-Sectional StudiesFemaleHumansInjections, IntramuscularInjections, SubcutaneousLigandsMaleMiddle AgedOctreotidePatient Reported Outcome MeasuresPeptides, CyclicPractice Patterns, Physicians'lanreotideLigandsOctreotidePeptides, CyclicReceptors, SomatostatinSomatostatinAcromegalyPatient reported outcomesQuestionnaireSomatostatin receptor ligandsTreatment satisfaction

Identifiers

PMID32736547
PMCPMC7393879
OpenAlexW3046734808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.